Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12249MR)

This product GTTS-WQ12249MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12249MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9694MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ12149MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ12346MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ7765MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ7704MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ7204MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ8200MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ15161MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW